COMP <GO>
SRPT vs XERS // RETURN ON INVESTED CAPITAL (ROIC)
Sarepta Therapeutics Inc. (NASDAQ) VS. Xeris Biopharma Holdings Inc. (NASDAQ) • 15-METRIC TALLY: SRPT 1
— XERS 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: XERS
LAST: $18.32 (-1.61%) • MKT CAP: $1.97B
roic
-35.00%
LAST: $10.17 (-5.04%) • MKT CAP: $1.95B
roic
16.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRPT VS. XERS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRPT | XERS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 16.00% | -51.00 | XERS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 83.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.14% | 1.46% | -16.60 | XERS | /fcf-yield <GO> |
| Operating Margin | -37.50% | 8.50% | -46.00 | XERS | /operating-margins <GO> |
| Net Profit Margin | -38.30% | 0.20% | -38.50 | XERS | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 43.70% | -39.40 | XERS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 2.11 | -1.91 | XERS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | XERS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 59.7 | -9.00 | XERS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.97B | $1.95B | $14.1M | SRPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRPT REV | XERS REV | SRPT GROSS % | XERS GROSS % | SRPT FCF | XERS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.86B | $291.8M | 98.0% | — | -$307.5M | $28.6M |
| FY 2024 | $1.79B | $203.1M | — | — | -$342.7M | -$37.0M |
| FY 2023 | $1.14B | $163.9M | — | — | -$501.0M | -$47.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRPT // BETA —
XERS // BETA —